首页 期刊 论文 学科刊群 资讯 加盟 关于
EN
image
Article(id=1199337301936538056, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1199337298941804946, articleNumber=null, orderNo=null, doi=10.11855/j.issn.0577-7402.1223.2023.0528, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=research-article, receivedDate=1653926400000, receivedDateStr=2022-05-31, revisedDate=null, revisedDateStr=null, acceptedDate=1665676800000, acceptedDateStr=2022-10-14, onlineDate=1763873895391, onlineDateStr=2025-11-23, pubDate=1706371200000, pubDateStr=2024-01-28, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1763873895391, onlineIssueDateStr=2025-11-23, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1763873895391, creator=13701087609, updateTime=1763873895391, updator=13701087609, issue=Issue{id=1199337298941804946, tenantId=1146029695717560320, journalId=1189873630562394117, year='2024', volume='49', issue='1', pageStart='1', pageEnd='120', issueExtLink='null', onlineDate='null', pubDate='null', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=0, createTime=1763873894677, creator=13701087609, updateTime=1763874094669, updator=13701087609, preIssue=null, nextIssue=null, ext={EN=IssueExt(id=1199338137823572576, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1199337298941804946, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1199338137823572577, tenantId=1146029695717560320, journalId=1189873630562394117, issueId=1199337298941804946, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null}, startPage=57, endPage=63, ext={EN=ArticleExt(id=1199337303253549521, articleId=1199337301936538056, tenantId=1146029695717560320, journalId=1189873630562394117, language=EN, title=Prognostic significance of MyD88L265P and CD79B mutations in primary central nervous system lymphoma, columnId=1190310109000602400, journalTitle=Medical Journal of Chinese People’s Liberation Army, columnName=Clinical Research, runingTitle=null, highlight=null, articleAbstract=

Objective To analyze the relationship between MyD88L265P and CD79B mutations in tumor tissue and the prognosis of primary central nervous system lymphoma (PCNSL). Methods 18 PCNSL patients with normal immune function (no history of HIV infection and immunosuppressants administration) who were diagnosed by craniotomy or stereotaxic biopsy in the Second Hospital of Lanzhou University from August 2018 to November 2020 were retrospectively analyzed. Real-time quantitative PCR and first-generation sequencing techniques were respectively used to detect MyD88L265P and CD79B mutations in tumor tissues of 18 PCNSL patients. Univariate analysis and Cox regression multivariate analysis were performed for indicators that may be associated with first progression-free survival (PFS) and overall survival in PCNSL. Results The mutation rate of MyD88L265P was 38.9%, the mutation rate of CD79B was 33.3%, and the co-mutation rate of MyD88L265P/CD79B was 27.8% in PCNSL tissue of 18 patients. Univariate analysis showed that the PCNSL patients with multiple lesions, deep involvement of lesions, and tissue CD79B mutation had a statistically significant shorter time of PFS (P<0.05). Multivariate analysis showed that deep lesion involvement(HR=0.135, 95%CI 0.023-0.799, P<0.05) and CD79B mutation (HR=0.149, 95%CI 0.028-0.800, P<0.05) in PCNSL tissue were independent prognostic factors for PCNSL patients. Conclusion The frequency of MyD88L265P and CD79B mutations was high in tumor tissues of 18 PCNSL patients, and these two gene mutations may be associated with poor prognosis of PCNSL, especially CD79B mutation.

, correspAuthors=Chong-Yang Wu, authorNote=null, correspAuthorsNote=
E-mail:
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, authorCompany=null, fund=null, authors=null, authorsList=Hao-Yun Jiang, Qi-Qi Jin, Li-Tian Zhang, Cui-Cui Li, Ning-Ning Yue, Chong-Yang Wu), CN=ArticleExt(id=1199337303840752108, articleId=1199337301936538056, tenantId=1146029695717560320, journalId=1189873630562394117, language=CN, title=MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤预后的影响, columnId=1190310109164180259, journalTitle=解放军医学杂志, columnName=临床研究, runingTitle=null, highlight=null, articleAbstract=

目的 探究MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤(PCNSL)患者预后的影响。方法 收集2018年8月-2020年11月于兰州大学第二医院经开颅手术或立体定位活检术确诊的18例免疫功能正常(无HIV感染及免疫抑制药服用病史)的PCNSL患者临床资料进行回顾性分析。分别采用实时荧光定量PCR和一代基因测序技术检测18例PCNSL患者肿瘤组织中MyD88L265P和CD79B基因突变情况。针对可能与PCNSL首次无疾病进展生存期(PFS)和总生存期相关的指标行单因素分析，并采用Cox 回归进行多因素分析。结果 18例PCNSL肿瘤组织MyD88L265P突变率为38.9%，CD79B突变率为33.3%，MyD88L265P/CD79B共突变率为27.8%。单因素分析结果显示，病灶多发、病灶深部受累、肿瘤组织CD79B突变患者的PFS时间更短(P<0.05)；多因素分析结果显示，病灶深部受累(HR=0.135，95%CI 0.023~0.799，P<0.05)、肿瘤组织CD79B突变(HR=0.149，95%CI 0.028~0.800，P<0.05)是PCNSL患者预后不良的独立危险因素。结论 本组PCNSL患者肿瘤组织MyD88L265P、CD79B突变频率较高，这两种基因突变尤其是CD79B突变可能与PCNSL不良预后相关。

, correspAuthors=吴重阳, authorNote=null, correspAuthorsNote=
吴重阳，E-mail：
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=fTcd8C4N/n/lM5N4d795jQ==, magXml=zJxCYbfMv3Dmsw6SfWWkwA==, pdfUrl=null, pdf=A52rvB8XdvC7UYj9PWbp1w==, pdfFileSize=1025269, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=gHPL63CNVSkyaBumVNJMFw==, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=WpTGJj4VL/1nXd26d3Y3uA==, mapNumber=null, authorCompany=null, fund=null, authors=

蒋皓云，硕士研究生，主要从事淋巴瘤相关的临床与基础研究

, authorsList=蒋皓云, 金祺祺, 张丽田, 李翠翠, 岳宁宁, 吴重阳)}, authors=[Author(id=1199376212591214704, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1199376212733821047, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376212591214704, language=EN, stringName=Hao-Yun Jiang, firstName=Hao-Yun, middleName=null, lastName=Jiang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376212868038784, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376212591214704, language=CN, stringName=蒋皓云, firstName=皓云, middleName=null, lastName=蒋, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=兰州大学第二医院血液科，甘肃兰州 730030, bio={"content":"

蒋皓云，硕士研究生，主要从事淋巴瘤相关的临床与基础研究

"}, bioImg=null, bioContent=

蒋皓云，硕士研究生，主要从事淋巴瘤相关的临床与基础研究

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])]), Author(id=1199376213035810948, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1199376213140668554, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213035810948, language=EN, stringName=Qi-Qi Jin, firstName=Qi-Qi, middleName=null, lastName=Jin, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376213237137553, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213035810948, language=CN, stringName=金祺祺, firstName=祺祺, middleName=null, lastName=金, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=兰州大学第二医院血液科，甘肃兰州 730030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])]), Author(id=1199376213337800857, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1199376213434269853, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213337800857, language=EN, stringName=Li-Tian Zhang, firstName=Li-Tian, middleName=null, lastName=Zhang, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376213513961638, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213337800857, language=CN, stringName=张丽田, firstName=丽田, middleName=null, lastName=张, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=兰州大学第二医院血液科，甘肃兰州 730030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])]), Author(id=1199376213618819248, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1199376213732065464, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213618819248, language=EN, stringName=Cui-Cui Li, firstName=Cui-Cui, middleName=null, lastName=Li, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376213920809153, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376213618819248, language=CN, stringName=李翠翠, firstName=翠翠, middleName=null, lastName=李, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=兰州大学第二医院血液科，甘肃兰州 730030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])]), Author(id=1199376214038249672, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1199376214155690190, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376214038249672, language=EN, stringName=Ning-Ning Yue, firstName=Ning-Ning, middleName=null, lastName=Yue, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376214281519316, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376214038249672, language=CN, stringName=岳宁宁, firstName=宁宁, middleName=null, lastName=岳, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=兰州大学第二医院血液科，甘肃兰州 730030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])]), Author(id=1199376214382182619, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, orderNo=5, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=wuchy0909@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1199376214495428834, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376214382182619, language=EN, stringName=Chong-Yang Wu, firstName=Chong-Yang, middleName=null, lastName=Wu, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1199376214575120617, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, authorId=1199376214382182619, language=CN, stringName=吴重阳, firstName=重阳, middleName=null, lastName=吴, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=兰州大学第二医院血液科，甘肃兰州 730030, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])])], keywords=[Keyword(id=1199376214759670008, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, orderNo=1, keyword=primary central nervous system lymphoma), Keyword(id=1199376214860333311, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, orderNo=2, keyword=MyD88 mutation), Keyword(id=1199376214944219395, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, orderNo=3, keyword=CD79B mutation), Keyword(id=1199376215061659911, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, orderNo=4, keyword=prognosis), Keyword(id=1199376215187489038, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, orderNo=1, keyword=原发性中枢神经系统淋巴瘤), Keyword(id=1199376215317512471, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, orderNo=2, keyword=MyD88L265P突变), Keyword(id=1199376215531421985, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, orderNo=3, keyword=CD79B突变), Keyword(id=1199376215657251111, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, orderNo=4, keyword=预后)], refs=[Reference(id=1199376218186416536, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2022, volume=36, issue=1, pageStart=147, pageEnd=159, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=Chukwueke U, Grommes C, Nayak L, journalName=Hematol Oncol Clin North Am, refType=null, unstructuredReference=Chukwueke U, Grommes C, Nayak L. Primary central nervous system lymphomas[J]. Hematol Oncol Clin North Am, 2022, 36(1): 147-159., articleTitle=Primary central nervous system lymphomas, refAbstract=null), Reference(id=1199376218287079834, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2022, volume=50, issue=8, pageStart=875, pageEnd=877, 880, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=郭旭, 朴浩哲, 隋锐, journalName=临床军医杂志, refType=null, unstructuredReference=郭旭, 朴浩哲, 隋锐, 等. 微小RNA-106b在中枢神经系统肿瘤中调控作用研究进展[J]. 临床军医杂志, 2022, 50(8): 875-877, 880., articleTitle=微小RNA-106b在中枢神经系统肿瘤中调控作用研究进展, refAbstract=null), Reference(id=1199376218370965917, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2006, volume=80, issue=2, pageStart=159, pageEnd=165, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=Jahnke K, Thiel E, Martus P, journalName=J Neurooncol, refType=null, unstructuredReference=Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors[J]. J Neurooncol, 2006, 80(2): 159-165., articleTitle=Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors, refAbstract=null), Reference(id=1199376218467434914, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2016, volume=18, issue=9, pageStart=1297, pageEnd=1303, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=Langner-Lemercier S, Houillier C, Soussain C, journalName=Neuro-Oncology, refType=null, unstructuredReference=Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network[J]. Neuro-Oncology, 2016, 18(9): 1297-1303., articleTitle=Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network, refAbstract=null), Reference(id=1199376218563903910, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2023, volume=49, issue=1, pageStart=209, pageEnd=214, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=秦毅丹, 李佳, 裴晓晨, journalName=吉林大学学报(医学版), refType=null, unstructuredReference=秦毅丹, 李佳, 裴晓晨, 等. 中枢神经系统淋巴瘤并发干燥综合征1例报告及文献复习[J]. 吉林大学学报(医学版), 2023, 49(1): 209-214., articleTitle=中枢神经系统淋巴瘤并发干燥综合征1例报告及文献复习, refAbstract=null), Reference(id=1199376218643595690, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2021, volume=193, issue=3, pageStart=497, pageEnd=505, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=Ferreri AJM, Calimeri T, Lopedote P, journalName=Br J Haematol, refType=null, unstructuredReference=Ferreri AJM, Calimeri T, Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study[J]. Br J Haematol, 2021, 193(3): 497-505., articleTitle=MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study, refAbstract=null), Reference(id=1199376218719093165, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2017, volume=31, issue=6, pageStart=833, pageEnd=843.e5, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=Lionakis MS, Dunleavy K, Roschewski M, journalName=Cancer Cell, refType=null, unstructuredReference=Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma[J]. Cancer Cell, 2017, 31(6): 833-843.e5., articleTitle=Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma, refAbstract=null), Reference(id=1199376218823950769, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2020, volume=55, issue=null, pageStart=58, pageEnd=62, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=Choi YS, journalName=Blood Res, refType=null, unstructuredReference=Choi YS. Recent advances in the management of primary central nervous system lymphoma[J]. Blood Res, 2020, 55: 58-62., articleTitle=Recent advances in the management of primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376218937196980, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2018, volume=9, issue=44, pageStart=27471, pageEnd=27486, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=Takashima Y, Sasaki Y, Hayano A, journalName=Oncotarget, refType=null, unstructuredReference=Takashima Y, Sasaki Y, Hayano A, et al. Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma[J]. Oncotarget, 2018, 9(44): 27471-27486., articleTitle=Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376219042054584, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2016, volume=42, issue=3, pageStart=279, pageEnd=290, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=Nakamura T, Tateishi K, Niwa T, journalName=Neuropathol Appl Neurobiol, refType=null, unstructuredReference=Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas[J]. Neuropathol Appl Neurobiol, 2016, 42(3): 279-290., articleTitle=Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas, refAbstract=null), Reference(id=1199376219146912190, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2019, volume=14, issue=1, pageStart=56, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=Niparuck P, Boonsakan P, Sutthippingkiat T, journalName=Diagn Pathol, refType=null, unstructuredReference=Niparuck P, Boonsakan P, Sutthippingkiat T, et al. Treatment outcome and prognostic factors in PCNSL[J]. Diagn Pathol, 2019, 14(1):56., articleTitle=Treatment outcome and prognostic factors in PCNSL, refAbstract=null), Reference(id=1199376219230798273, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2020, volume=133, issue=12, pageStart=1462, pageEnd=1469, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=Zhang Y, Zhou DB, journalName=Chin Med J, refType=null, unstructuredReference=Zhang Y, Zhou DB. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment[J]. Chin Med J, 2020, 133(12): 1462-1469., articleTitle=Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment, refAbstract=null), Reference(id=1199376219314684356, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2017, volume=37, issue=6, pageStart=509, pageEnd=516, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=Zheng M, Perry A M, Bierman P, journalName=Neuropathology, refType=null, unstructuredReference=Zheng M, Perry A M, Bierman P, et al. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma[J]. Neuropathology, 2017, 37(6): 509-516., articleTitle=Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma, refAbstract=null), Reference(id=1199376219436319177, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2022, volume=13, issue=1, pageStart=2558, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=Radke J, Ishaque N, Koll R, journalName=Nat Commun, refType=null, unstructuredReference=Radke J, Ishaque N, Koll R, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma[J]. Nat Commun, 2022, 13(1): 2558., articleTitle=The genomic and transcriptional landscape of primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376219528593868, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2017, volume=177, issue=3, pageStart=492, pageEnd=494, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=Hattori K, Sakata-Yanagimoto M, Okoshi Y, journalName=Br J Haematol, refType=null, unstructuredReference=Hattori K, Sakata-Yanagimoto M, Okoshi Y, et al. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma[J]. Br J Haematol, 2017, 177(3): 492-494., articleTitle=MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376219612479951, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2019, volume=133, issue=5, pageStart=436, pageEnd=445, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=Grommes C, Tang SS, Wolfe J, journalName=Blood, refType=null, unstructuredReference=Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma[J]. Blood, 2019, 133(5): 436-445., articleTitle=Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma, refAbstract=null), Reference(id=1199376219729920470, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2022, volume=45, issue=1, pageStart=51, pageEnd=57, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=陈锟, 马晶晶, 王迪, journalName=中华检验医学杂志, refType=null, unstructuredReference=陈锟,马晶晶, 王迪, 等. 脑脊液MyD88L265P基因突变对原发性中枢神经系统淋巴瘤预后的影响[J]. 中华检验医学杂志, 2022, 45(1): 51-57., articleTitle=脑脊液MyD88L265P基因突变对原发性中枢神经系统淋巴瘤预后的影响, refAbstract=null), Reference(id=1199376219830583767, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2016, volume=131, issue=6, pageStart=865, pageEnd=875, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=Fukumura K, Kawazu M, Kojima S, journalName=Acta Neuropathol, refType=null, unstructuredReference=Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma[J]. Acta Neuropathol, 2016, 131(6): 865-875., articleTitle=Genomic characterization of primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376219939635673, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2018, volume=109, issue=1, pageStart=225, pageEnd=230, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=Hattori K, Sakata-Yanagimoto M, Suehara Y, journalName=Cancer Sci, refType=null, unstructuredReference=Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma[J]. Cancer Sci, 2018, 109(1): 225-230., articleTitle=Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma, refAbstract=null), Reference(id=1199376220031910363, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2018, volume=20, issue=10, pageStart=1059, pageEnd=1069, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=Zhou YY, Liu W, Xu ZJ, journalName=Neoplasia, refType=null, unstructuredReference=Zhou YY, Liu W, Xu ZJ, et al. Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes[J]. Neoplasia, 2018, 20(10): 1059-1069., articleTitle=Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes, refAbstract=null), Reference(id=1199376220140962272, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2018, volume=140, issue=3, pageStart=509, pageEnd=517, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=Zorofchian S, El-Achi H, Yan YQ, journalName=J Neuro-Oncol, refType=null, unstructuredReference=Zorofchian S, El-Achi H, Yan YQ, et al. Characterization of genomic alterations in primary central nervous system lymphomas[J]. J Neuro-Oncol, 2018, 140(3): 509-517., articleTitle=Characterization of genomic alterations in primary central nervous system lymphomas, refAbstract=null), Reference(id=1199376220233236960, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2011, volume=35, issue=5, pageStart=746, pageEnd=756, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=O'neill SK, Getahun A, Gauld SB, journalName=Immunity, refType=null, unstructuredReference=O'neill SK, Getahun A, Gauld SB, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy[J]. Immunity, 2011, 35(5): 746-756., articleTitle=Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy, refAbstract=null), Reference(id=1199376220350677476, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, doi=null, pmid=null, pmcid=null, year=2019, volume=102, issue=2, pageStart=191, pageEnd=196, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=Yonese I, Takase H, Yoshimori M, journalName=Eur J Haematol, refType=null, unstructuredReference=Yonese I, Takase H, Yoshimori M, et al. CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential[J]. Eur J Haematol, 2019, 102(2): 191-196., articleTitle=CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential, refAbstract=null)], funds=[Fund(id=1199376217376915837, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, awardId=8226010026, language=EN, fundingSource=National Natural Science Foundation of China(8226010026), fundOrder=null, country=null), Fund(id=1199376217712460167, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, awardId=8226010026, language=CN, fundingSource=国家自然科学基金(8226010026), fundOrder=null, country=null), Fund(id=1199376217880232331, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, awardId=201710, language=EN, fundingSource=Project of "Cuiying Graduate Instructor" Training in the Second Hospital of Lanzhou University(201710), fundOrder=null, country=null), Fund(id=1199376217968312720, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, awardId=201710, language=CN, fundingSource=兰州大学第二医院“萃英研究生指导教师”培育计划(201710), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1199376212415053928, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, xref=null, ext=[AuthorCompanyExt(id=1199376212423442537, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China), AuthorCompanyExt(id=1199376212431831146, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, companyId=1199376212415053928, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=兰州大学第二医院血液科，甘肃兰州 730030)])], figs=[ArticleFig(id=1199376215900520757, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Fig.1, caption=Effects of number of lesions, deep involvement of the lesion, and CD79B mutation in the tumor on PFS and OS in 18 patients with PCNSL, figureFileSmall=QvSx1ezK76ZjtYfZiahv4g==, figureFileBig=uwVmx1aKmOPJcVuh5BAIHQ==, tableContent=null), ArticleFig(id=1199376216034738494, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=图1, caption=18例PCNSL患者的病灶数量、病灶深部受累、肿瘤组织CD79B突变与PFS、OS的关系

PCNSL. 原发性中枢神经系统淋巴瘤；PFS. 无进展生存期；OS. 总生存期

, figureFileSmall=QvSx1ezK76ZjtYfZiahv4g==, figureFileBig=uwVmx1aKmOPJcVuh5BAIHQ==, tableContent=null), ArticleFig(id=1199376216164761923, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Tab.1, caption=

Primer sequences for PCR amplification of CD79B

, figureFileSmall=null, figureFileBig=null, tableContent=
基因引物序列
CD79B-1正义：5'-GTAAAACGACGGCCAGTGCGGTGCAGTTACACGTTTTCC-3'
反义：5'-GGAAACAGCTATGACCATGAGATGAGAGCAAACCCCACA-3'
CD79B-2正义：5'-GTAAAACGACGGCCAGTGGGAAGTAGCTCCGGGAACAT-3'
反义：5'-GGAAACAGCTATGACCATGGGACACAGGACATAGTCGCA-3'
CD79B-3-1正义：5'-GTAAAACGACGGCCAGTGCAGGAAGATGCCAAGCGGAA-3'
反义：5'-GGAAACAGCTATGACCATGTTCTGGGACTCTTCCATGCG-3'
CD79B-3-2正义：5'-GTAAAACGACGGCCAGTGAGAGCCCACGTITCATAGCC-3'
反义：5'-GGAAACAGCTATGACCATCCGAGGTGTTGTTGCACTTC-3'
CD79B-3-3正义：5'-GTAAAACGACGGCCAGTGCCAGAACGAATCTCTCGCCA-3'
反义：5'-GGAAACAGCTATGACCATGGACCATCACCACAAGAGGCA-3'
CD79B-4正义：5'-GTAAAACGACGGCCAGTGTAAAAGGTGGACTGTGGCCC-3'
反义：5'-GGAAACAGCTATGACCATGTATGCCTGGCCTATGCGGT-3'
CD79B-5正义：5'-GTAAAACGACGGCCAGTGCTGGGGGACACTAACACTCTG-3'
反义：5'-GGAAACAGCTATGACCATGGCCCTGGAGACATTAAGTGGA-3'
CD79B-6正义：5'-GTAAAACGACGGCCAGTGTGGCCACTATCTCIGGTGT-3'
反义：5'-GGAAACAGCTATGACCATGGAAAGGGGTTGGGCCATGA-3'
), ArticleFig(id=1199376216265425227, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=表1, caption=

PCR法扩增 CD79B基因采用的引物序列

, figureFileSmall=null, figureFileBig=null, tableContent=
基因引物序列
CD79B-1正义：5'-GTAAAACGACGGCCAGTGCGGTGCAGTTACACGTTTTCC-3'
反义：5'-GGAAACAGCTATGACCATGAGATGAGAGCAAACCCCACA-3'
CD79B-2正义：5'-GTAAAACGACGGCCAGTGGGAAGTAGCTCCGGGAACAT-3'
反义：5'-GGAAACAGCTATGACCATGGGACACAGGACATAGTCGCA-3'
CD79B-3-1正义：5'-GTAAAACGACGGCCAGTGCAGGAAGATGCCAAGCGGAA-3'
反义：5'-GGAAACAGCTATGACCATGTTCTGGGACTCTTCCATGCG-3'
CD79B-3-2正义：5'-GTAAAACGACGGCCAGTGAGAGCCCACGTITCATAGCC-3'
反义：5'-GGAAACAGCTATGACCATCCGAGGTGTTGTTGCACTTC-3'
CD79B-3-3正义：5'-GTAAAACGACGGCCAGTGCCAGAACGAATCTCTCGCCA-3'
反义：5'-GGAAACAGCTATGACCATGGACCATCACCACAAGAGGCA-3'
CD79B-4正义：5'-GTAAAACGACGGCCAGTGTAAAAGGTGGACTGTGGCCC-3'
反义：5'-GGAAACAGCTATGACCATGTATGCCTGGCCTATGCGGT-3'
CD79B-5正义：5'-GTAAAACGACGGCCAGTGCTGGGGGACACTAACACTCTG-3'
反义：5'-GGAAACAGCTATGACCATGGCCCTGGAGACATTAAGTGGA-3'
CD79B-6正义：5'-GTAAAACGACGGCCAGTGTGGCCACTATCTCIGGTGT-3'
反义：5'-GGAAACAGCTATGACCATGGAAAGGGGTTGGGCCATGA-3'
), ArticleFig(id=1199376216382865742, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Tab.2, caption=

Clinical data of 18 patients with primary central nervous system lymphoma

, figureFileSmall=null, figureFileBig=null, tableContent=
序号性别

年龄
(岁)

病史组织学类型分型肿瘤位置肿瘤组织获取方式治疗方案疗效随访时间(月)随访结果
1男29无DLBCLGCB右侧额叶经额脑病损切除术6个疗程R-MTCR43存活
2男57无DLBCLGCB右侧颞顶叶经丘脑病损切除术6个疗程R-MTCR30存活
3女56无DLBCLGCB鞍区、右侧额颞叶经额脑病损切除术6个疗程R-MTPD(确诊4个月后)41存活
4男58无DLBCLGCB右侧顶枕叶大脑深部病损切除术6个疗程R-MTCR25存活
5女50子宫切除术DLBCLGCB右侧额叶立体定向活检5个疗程R-MT+2个疗程R-MA+放疗DOD(确诊5个月后PD，随访至19个月死亡)19死亡
6男60无DLBCL非GCB双侧视神经框内段立体定向活检6个疗程R-TMPR40存活
7男64无DLBCL非GCB右侧顶叶经额脑病损切除术

4个疗程R-MT+
2个疗程RM

PR35存活
8女46无DLBCL非GCB右侧基底节、右侧颞叶立体定向活检6个疗程R-MTPD(确诊2个月后)32存活
9男54无DLBCL非GCB胼胝体、左侧侧脑室颅底病损切除术6个疗程R-MTCR32存活
10男55无DLBCL非GCB小脑小脑半球病损切除术10个疗程R-MTCR21存活
11女59无DLBCL非GCB左侧额顶叶、胼胝体经顶脑病损切除术8个疗程R-MTDOD(确诊3个月后PD，随访至22个月死亡)22死亡
12男56无DLBCL非GCB右侧基底节、左侧丘脑、大脑脚、脑干立体定向活检

2个疗程R-MT+
4R-MA

DOD(确诊3个月后PD，随访至8个月死亡)20死亡
13男47无DLBCL非GCB左侧额叶、基底节区颅底病损切除术6个疗程R-MT+放疗PD(确诊4个月后)18存活
14女60无DLBCL非GCB右侧额叶大脑深部病损切除术7个疗程RMDPR16存活
15男33无DLBCLGCB左侧额顶颞叶、侧脑室后脚旁立体定向活检8个疗程RMD+自体造血干细胞移植PR16存活
16女59无DLBCL非GCB左侧大脑半球颅脑病损切除术7个疗程RMDPD(确诊4个月后)17存活
17男42无DLBCLGCB双侧基底节、右侧丘脑、脑干、双侧颞叶立体定向活检2个疗程R-MTDOD(确诊2个月后PD并死亡)23死亡
18男51无DLBCLGCB脑干、胼胝体、右侧基底节、双侧楔叶立体定向活检6个疗程R-MTPD(确诊3个月后)28存活
), ArticleFig(id=1199376216496111955, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=表2, caption=

18例原发性中枢神经系统淋巴瘤的临床资料

, figureFileSmall=null, figureFileBig=null, tableContent=
序号性别

年龄
(岁)

病史组织学类型分型肿瘤位置肿瘤组织获取方式治疗方案疗效随访时间(月)随访结果
1男29无DLBCLGCB右侧额叶经额脑病损切除术6个疗程R-MTCR43存活
2男57无DLBCLGCB右侧颞顶叶经丘脑病损切除术6个疗程R-MTCR30存活
3女56无DLBCLGCB鞍区、右侧额颞叶经额脑病损切除术6个疗程R-MTPD(确诊4个月后)41存活
4男58无DLBCLGCB右侧顶枕叶大脑深部病损切除术6个疗程R-MTCR25存活
5女50子宫切除术DLBCLGCB右侧额叶立体定向活检5个疗程R-MT+2个疗程R-MA+放疗DOD(确诊5个月后PD，随访至19个月死亡)19死亡
6男60无DLBCL非GCB双侧视神经框内段立体定向活检6个疗程R-TMPR40存活
7男64无DLBCL非GCB右侧顶叶经额脑病损切除术

4个疗程R-MT+
2个疗程RM

PR35存活
8女46无DLBCL非GCB右侧基底节、右侧颞叶立体定向活检6个疗程R-MTPD(确诊2个月后)32存活
9男54无DLBCL非GCB胼胝体、左侧侧脑室颅底病损切除术6个疗程R-MTCR32存活
10男55无DLBCL非GCB小脑小脑半球病损切除术10个疗程R-MTCR21存活
11女59无DLBCL非GCB左侧额顶叶、胼胝体经顶脑病损切除术8个疗程R-MTDOD(确诊3个月后PD，随访至22个月死亡)22死亡
12男56无DLBCL非GCB右侧基底节、左侧丘脑、大脑脚、脑干立体定向活检

2个疗程R-MT+
4R-MA

DOD(确诊3个月后PD，随访至8个月死亡)20死亡
13男47无DLBCL非GCB左侧额叶、基底节区颅底病损切除术6个疗程R-MT+放疗PD(确诊4个月后)18存活
14女60无DLBCL非GCB右侧额叶大脑深部病损切除术7个疗程RMDPR16存活
15男33无DLBCLGCB左侧额顶颞叶、侧脑室后脚旁立体定向活检8个疗程RMD+自体造血干细胞移植PR16存活
16女59无DLBCL非GCB左侧大脑半球颅脑病损切除术7个疗程RMDPD(确诊4个月后)17存活
17男42无DLBCLGCB双侧基底节、右侧丘脑、脑干、双侧颞叶立体定向活检2个疗程R-MTDOD(确诊2个月后PD并死亡)23死亡
18男51无DLBCLGCB脑干、胼胝体、右侧基底节、双侧楔叶立体定向活检6个疗程R-MTPD(确诊3个月后)28存活
), ArticleFig(id=1199376216596775257, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Tab.3, caption=

Related influencing factors to PFS of 18 patients with PCNSL

, figureFileSmall=null, figureFileBig=null, tableContent=
影响因素

例数
(%)

PFS[月,

M(95%CI)]

χ²P
年龄0.0080.930
≥50岁13(72.2)5
<50岁5(27.8)4
性别3.9040.079
男12(66.7)未达到
女6(33.3)4
病灶数量4.4950.034
单发9(50.0)未达到
多发9(50.0)3
病灶深部受累5.7040.017
是8(44.4)3
否10(55.6)未达到
病损切除术3.1660.075
是11(61.1)未达到
否7(38.9)3
ECOG评分0.0000.999
≥214(77.8)4
<24(22.2)5
LDH水平0.5550.456
正常15(83.3)未达到
异常3(16.7)4
BCL22.7190.099
阳性15(83.3)
阴性3(16.7)
BCL60.2740.600
阳性15(83.3)未达到
阴性3(16.7)4
MUM11.6580.198
阳性16(88.9)
阴性2(11.1)
分型1.0210.312
GCB8(44.4)未达到
非GCB10(55.6)4
MyD88L265P突变0.3820.537
突变型7(38.9)4(2~40)
野生型11(61.1)未达到
CD79B突变5.4110.020
突变型6(33.3)3(2~40)
野生型12(66.7)未达到
MyD88L265P/CD79B共突变3.3400.068
是5(27.8)4(2~40)
否13(72.2)未达到
), ArticleFig(id=1199376216735187297, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=表3, caption=

18例PCNSL 患者PFS的相关影响因素

, figureFileSmall=null, figureFileBig=null, tableContent=
影响因素

例数
(%)

PFS[月,

M(95%CI)]

χ²P
年龄0.0080.930
≥50岁13(72.2)5
<50岁5(27.8)4
性别3.9040.079
男12(66.7)未达到
女6(33.3)4
病灶数量4.4950.034
单发9(50.0)未达到
多发9(50.0)3
病灶深部受累5.7040.017
是8(44.4)3
否10(55.6)未达到
病损切除术3.1660.075
是11(61.1)未达到
否7(38.9)3
ECOG评分0.0000.999
≥214(77.8)4
<24(22.2)5
LDH水平0.5550.456
正常15(83.3)未达到
异常3(16.7)4
BCL22.7190.099
阳性15(83.3)
阴性3(16.7)
BCL60.2740.600
阳性15(83.3)未达到
阴性3(16.7)4
MUM11.6580.198
阳性16(88.9)
阴性2(11.1)
分型1.0210.312
GCB8(44.4)未达到
非GCB10(55.6)4
MyD88L265P突变0.3820.537
突变型7(38.9)4(2~40)
野生型11(61.1)未达到
CD79B突变5.4110.020
突变型6(33.3)3(2~40)
野生型12(66.7)未达到
MyD88L265P/CD79B共突变3.3400.068
是5(27.8)4(2~40)
否13(72.2)未达到
), ArticleFig(id=1199376216844239206, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Tab.4, caption=

Result of Cox regression analysis on the risk factors for PFS in 18 patients with PCNSL

, figureFileSmall=null, figureFileBig=null, tableContent=
参数βSEWald χ2PExp(β)Exp(β)95%CI
病灶数量0.2740.9250.0880.7670.7600.124~4.658
病灶深部受累2.0040.9084.8690.0270.1350.023~0.799
CD79B突变1.9050.8584.9320.0260.1490.028~0.800
), ArticleFig(id=1199376216957485418, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=表4, caption=

18例PCNSL患者PFS影响因素的Cox回归分析结果

, figureFileSmall=null, figureFileBig=null, tableContent=
参数βSEWald χ2PExp(β)Exp(β)95%CI
病灶数量0.2740.9250.0880.7670.7600.124~4.658
病灶深部受累2.0040.9084.8690.0270.1350.023~0.799
CD79B突变1.9050.8584.9320.0260.1490.028~0.800
), ArticleFig(id=1199376217041371502, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=EN, label=Tab.5, caption=

Effects of the mutations of MyD88L265P and CD79B on therapeutic response in 13 patients with PCNSL

, figureFileSmall=null, figureFileBig=null, tableContent=
基因突变例数(%)mPFSmOS
ZPZP
MyD88L265P基因突变-2.1600.019-0.178>0.05
有效3(42.9)
无效4(57.1)
CD79B基因突变-1.8790.044-1.389>0.05
有效2(33.3)
无效4(66.7)
), ArticleFig(id=1199376217188172148, tenantId=1146029695717560320, journalId=1189873630562394117, articleId=1199337301936538056, language=CN, label=表5, caption=

MyD88L265P及CD79B基因突变对13例PCNSL患者治疗反应的影响

, figureFileSmall=null, figureFileBig=null, tableContent=
基因突变例数(%)mPFSmOS
ZPZP
MyD88L265P基因突变-2.1600.019-0.178>0.05
有效3(42.9)
无效4(57.1)
CD79B基因突变-1.8790.044-1.389>0.05
有效2(33.3)
无效4(66.7)
)], attaches=null, journal=Journal(id=1146441329971666965, delFlag=0, nameCn=解放军医学杂志, nameEn=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, issn=0577-7402, eissn=null, cn=11-1056/R, coden=null, periodic=0, language=CN, oaType=是, ccby=CC BY-NC-ND, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=6srot5PcoYX30Oa4xeTmeg==, journalPrice=null, startedYear=null, abbrevIsoEn=null, journalRemark=null, publicationField=null, createdTime=1751262512917, updatedTime=1761735725513, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=M, firstLetterEn=M, subjectCode=Life Sciences, subjectName=Life Sciences, subjectCodeEn=Life Sciences, subjectNameEn=null, picCn=6srot5PcoYX30Oa4xeTmeg==, picEn=ELwBh5xqrSTlIs7HmSNt2Q==, jcr=null, cjcr=null, exts=[JournalExt(id=1190369167564968109, language=CN, name=解放军医学杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725537, updatedTime=1761735725537, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1190369167615299758, language=EN, name=Medical Journal of Chinese People’s Liberation Army, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1761735725549, updatedTime=1761735725549, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=#, submissionEditorUrl=#, submissionReviewUrl=#, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1189873630562394117, websiteList=[Website(id=1189873845923287108, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN, language=CN, createTime=1761617631655, createBy=18614031015, updateTime=1761622010471, updateBy=18614031015, name=解放军医学杂志-中文, tplId=1146099689490845704, title=解放军医学杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924939378520839, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=articleTextType, value=kx, createTime=1761629813284, updateTime=1761629813284, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939353355012, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=banner, value=null, createTime=1761629813278, updateTime=1761629813278, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939399492362, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=grayFlag, value=0, createTime=1761629813289, updateTime=1761629813289, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939344966403, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629813276, updateTime=1761629813276, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939412075276, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=minRunFlag, value=0, createTime=1761629813292, updateTime=1761629813292, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939374326534, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/file/pic, createTime=1761629813283, updateTime=1761629813283, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939407880971, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=silenceFlag, value=0, createTime=1761629813291, updateTime=1761629813291, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939361743621, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1761629813280, updateTime=1761629813280, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939386909448, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeColor, value=null, createTime=1761629813286, updateTime=1761629813286, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924939395298057, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873845923287108, code=themeStyle, value=null, createTime=1761629813288, updateTime=1761629813288, creator=18614031015, updator=18614031015)]), Website(id=1189873846057504839, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1189873630562394117, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN, language=EN, createTime=1761617631687, createBy=18614031015, updateTime=1761622030030, updateBy=18614031015, name=解放军医学杂志-英文, tplId=1146101810881728533, title=Medical Journal of Chinese People’s Liberation Army, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1189924968168223505, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=articleTextType, value=kx, createTime=1761629820148, updateTime=1761629820148, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968147251982, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=banner, value=null, createTime=1761629820143, updateTime=1761629820143, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968185000724, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=grayFlag, value=0, createTime=1761629820152, updateTime=1761629820152, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968138863373, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=logo, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic?fileId=+zXjYVhun8ZOAA6+aKx2hw==, createTime=1761629820141, updateTime=1761629820141, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968197583638, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=minRunFlag, value=0, createTime=1761629820155, updateTime=1761629820155, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968159834896, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/file/pic, createTime=1761629820146, updateTime=1761629820146, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968193389333, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=silenceFlag, value=0, createTime=1761629820154, updateTime=1761629820154, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968155640591, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1761629820145, updateTime=1761629820145, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968172417810, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeColor, value=null, createTime=1761629820149, updateTime=1761629820149, creator=18614031015, updator=18614031015), WebsiteProps(id=1189924968180806419, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1189873846057504839, code=themeStyle, value=null, createTime=1761629820151, updateTime=1761629820151, creator=18614031015, updator=18614031015)])], journalTitle=解放军医学杂志, weixinUrl=null, journalUrl=http://zh.jfjyxzz.org.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Medical Journal of Chinese People’s Liberation Army, journalPhotoCn=6srot5PcoYX30Oa4xeTmeg==, journalPhotoEn=ELwBh5xqrSTlIs7HmSNt2Q==, journalFirstLetter=M, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false), detailUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/10.11855/j.issn.0577-7402.1223.2023.0528, detailUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/10.11855/j.issn.0577-7402.1223.2023.0528, pdfUrlCn=https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/PDF/10.11855/j.issn.0577-7402.1223.2023.0528, pdfUrlEn=https://castjournals.cast.org.cn/joweb/jfjyxzz/EN/PDF/10.11855/j.issn.0577-7402.1223.2023.0528, aliStartDate=null, aliEndDate=null, collectionFlag=false, citedCount=null, citedUrl=null, reference=null)
收藏切换
MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤预后的影响
收藏切换
PDF下载
蒋皓云 , 金祺祺 , 张丽田 , 李翠翠 , 岳宁宁 , 吴重阳 *
解放军医学杂志 | 临床研究 2024,49(1): 57-63
收起
收藏切换
解放军医学杂志 | 临床研究 2024, 49(1): 57-63
MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤预后的影响
全屏
蒋皓云, 金祺祺, 张丽田, 李翠翠, 岳宁宁, 吴重阳*
作者信息
  • 兰州大学第二医院血液科，甘肃兰州 730030

    • 蒋皓云，硕士研究生，主要从事淋巴瘤相关的临床与基础研究

通讯作者:

吴重阳，E-mail：
Prognostic significance of MyD88L265P and CD79B mutations in primary central nervous system lymphoma
Hao-Yun Jiang, Qi-Qi Jin, Li-Tian Zhang, Cui-Cui Li, Ning-Ning Yue, Chong-Yang Wu*
Affiliations
  • Department of Hematology, the Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, China
出版时间: 2024-01-28 doi: 10.11855/j.issn.0577-7402.1223.2023.0528
文章导航
收藏切换
摘要
收起

目的 探究MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤(PCNSL)患者预后的影响。方法 收集2018年8月-2020年11月于兰州大学第二医院经开颅手术或立体定位活检术确诊的18例免疫功能正常(无HIV感染及免疫抑制药服用病史)的PCNSL患者临床资料进行回顾性分析。分别采用实时荧光定量PCR和一代基因测序技术检测18例PCNSL患者肿瘤组织中MyD88L265P和CD79B基因突变情况。针对可能与PCNSL首次无疾病进展生存期(PFS)和总生存期相关的指标行单因素分析，并采用Cox 回归进行多因素分析。结果 18例PCNSL肿瘤组织MyD88L265P突变率为38.9%，CD79B突变率为33.3%，MyD88L265P/CD79B共突变率为27.8%。单因素分析结果显示，病灶多发、病灶深部受累、肿瘤组织CD79B突变患者的PFS时间更短(P<0.05)；多因素分析结果显示，病灶深部受累(HR=0.135，95%CI 0.023~0.799，P<0.05)、肿瘤组织CD79B突变(HR=0.149，95%CI 0.028~0.800，P<0.05)是PCNSL患者预后不良的独立危险因素。结论 本组PCNSL患者肿瘤组织MyD88L265P、CD79B突变频率较高，这两种基因突变尤其是CD79B突变可能与PCNSL不良预后相关。

原发性中枢神经系统淋巴瘤  /  MyD88L265P突变  /  CD79B突变  /  预后

Objective To analyze the relationship between MyD88L265P and CD79B mutations in tumor tissue and the prognosis of primary central nervous system lymphoma (PCNSL). Methods 18 PCNSL patients with normal immune function (no history of HIV infection and immunosuppressants administration) who were diagnosed by craniotomy or stereotaxic biopsy in the Second Hospital of Lanzhou University from August 2018 to November 2020 were retrospectively analyzed. Real-time quantitative PCR and first-generation sequencing techniques were respectively used to detect MyD88L265P and CD79B mutations in tumor tissues of 18 PCNSL patients. Univariate analysis and Cox regression multivariate analysis were performed for indicators that may be associated with first progression-free survival (PFS) and overall survival in PCNSL. Results The mutation rate of MyD88L265P was 38.9%, the mutation rate of CD79B was 33.3%, and the co-mutation rate of MyD88L265P/CD79B was 27.8% in PCNSL tissue of 18 patients. Univariate analysis showed that the PCNSL patients with multiple lesions, deep involvement of lesions, and tissue CD79B mutation had a statistically significant shorter time of PFS (P<0.05). Multivariate analysis showed that deep lesion involvement(HR=0.135, 95%CI 0.023-0.799, P<0.05) and CD79B mutation (HR=0.149, 95%CI 0.028-0.800, P<0.05) in PCNSL tissue were independent prognostic factors for PCNSL patients. Conclusion The frequency of MyD88L265P and CD79B mutations was high in tumor tissues of 18 PCNSL patients, and these two gene mutations may be associated with poor prognosis of PCNSL, especially CD79B mutation.

primary central nervous system lymphoma  /  MyD88 mutation  /  CD79B mutation  /  prognosis
蒋皓云, 金祺祺, 张丽田, 李翠翠, 岳宁宁, 吴重阳. MyD88L265P及CD79B基因突变对原发性中枢神经系统淋巴瘤预后的影响. 解放军医学杂志, 2024 , 49 (1) : 57 -63 . DOI: 10.11855/j.issn.0577-7402.1223.2023.0528
Hao-Yun Jiang, Qi-Qi Jin, Li-Tian Zhang, Cui-Cui Li, Ning-Ning Yue, Chong-Yang Wu. Prognostic significance of MyD88L265P and CD79B mutations in primary central nervous system lymphoma[J]. Medical Journal of Chinese People’s Liberation Army, 2024 , 49 (1) : 57 -63 . DOI: 10.11855/j.issn.0577-7402.1223.2023.0528
正文
收起
原发性中枢神经系统淋巴瘤(primary central nervous system lymphoma，PCNSL)是一种罕见的侵袭性结外非霍奇金淋巴瘤，病变局限于脑、脊髓、软脑膜或眼[1-2]。由于化疗药物难以有效通过血脑屏障，PCNSL患者治疗效果不佳，且复发率高、预后差[3-5]。目前PCNSL诊断的金标准仍为组织活检，联合特异性基因突变及脑脊液特征性细胞因子检测可提高诊断的敏感度[6]。多项研究发现，MyD88L265P、CD79B基因为PCNSL热点突变[7-10]，对PCNSL的诊断、预后及靶向治疗具有潜在临床价值。本研究检测18例PCNSL患者肿瘤组织中MyD88L265P、CD79B的突变频率，并回顾性分析其与PCNSL患者预后的相关性，旨在为PCNSL的临床诊治提供依据。
1 资料与方法
收起
1.1 研究对象
选择2018年8月-2020年11月在兰州大学第二医院诊治的18例PCNSL患者作为研究对象。纳入标准：(1)依据2016年世界卫生组织(WHO)造血和淋巴组织肿瘤分类的诊断标准诊断为PCNSL，且初诊时均有明确的病理学诊断证据；(2)临床检验及病理资料完整；(3)免疫功能正常(无HIV感染史、无免疫抑制药服用病史)；(4)接受以利妥昔单抗(Rituximab，R)、氨甲蝶呤(methotrexate，M)、替莫唑胺(temozolomide，T)/脂质体多柔比星(dorubicin liposomes，D)/阿糖胞苷(cytarabine，A)(R 375 mg/m2 d0 ivgtt，M 3.0~3.5 mg/m2 d1 ivgtt，T 200 mg/m2 d1~d5 po，D 50 mg/m2 ivgtt，A 2.0 mg/m2 q12 d2~d3 ivgtt)为基础治疗方案，依照患者病情采用上述治疗方案。排除标准：(1)系统性弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma，DLBCL)中枢浸润；(2)既往存在其他恶性肿瘤病史；(3)存在精神性疾病。
1.2 方法
收集PCNSL患者的临床病例资料，并对其临床指标及肿瘤组织中MyD88L265P、CD79B的突变频率与预后的相关性进行回顾性分析。患者生存分析采用Kaplan-Meier 法。
1.2.1 免疫组化及结果判定
肿瘤组织标本经开颅手术或立体定位活检术获取，经常规组织包埋、切片和染色，并采用Envision二步法进行免疫组织化学染色。本研究所使用的一抗包括：抗CD20、CD79a、CD10、CD23、BCL2、BCL6、MUM1、cyclin D1及Ki67抗体(福州迈新公司)。所有免疫组织化学染色结果均由兰州大学第二医院两名具有高级职称的病理科医师判定为阳性或阴性。
1.2.2 MYD88L265P及CD79B基因突变检测
分析存档的5~10 μm厚的4%多聚甲醛溶液固定、石蜡包埋脑活检切片，分别采用实时荧光定量PCR、一代基因测序技术对MyD88L265P及CD79B突变进行全外显子检测。采用ABI7500 荧光定量仪(美国赛默飞世尔科技公司)检测MyD88L265P突变，PCR正义引物5'-GGGGATGGCTGTTGTTAA-3'，反义引物5'-GC-AGGGGTTGGTGTAGTC-3'。采用一代基因测序技术检测CD79B突变，采用的PCR扩增引物序列见表1。PCR产物经15%琼脂糖凝胶电泳，产物纯化，并用ABI 3730XL测序仪(美国ABI)测序。
1.2.3 随访
患者无进展生存期(progression-free survival，PFS)定义为初次诊断至疾病进展、死亡或最后一次随访的时间；总生存期(overall survival，OS)定义为初次诊断至死亡或最后一次随访的时间；随访时间截至2022年3月31日。生存时间以“月”为单位计算，中位随访时间为24.5(16~43)个月。
1.3 统计学处理
采用SPSS 26.0软件进行统计分析。计数资料以例(%)表示，组间比较采用χ2检验。Kaplan-Meier 生存曲线之间的差异采用双尾Log-rank检验。P<0.05为差异有统计学意义。
2 结果
收起
2.1 临床资料
本组18例PCNSL患者发病年龄为52.0(29.0~64.0)岁，其中≥50岁13例(占72.2%)。9例为单发肿瘤，9例为多发肿瘤，其中8例深部脑组织受累(胼胝体、基底节、脑干或小脑)。18例组织学分型均为DLBCL；按细胞来源分型，8例为生发中心来源(germinal center B-cell，GCB)，10例为非GCB。临床表现多样，10例(占55.6%)以头痛、头晕为首发症状，肢体无力11例(占61.1%)，视物模糊6例(占33.3%)，意识障碍2例(占11.1%)，言语功能障碍4例(占22.2%)。除1例两个疗程治疗无效死亡，其余17例均接受至少6个疗程化疗；患者在第4疗程后接受疗效评估，5例完全缓解(complete response，CR)，4例部分缓解(partial response，PR)，8例疾病进展(progressive disease，PD)。截至2022年3月31日，4例死亡(表2)。
2.2 MyD88L265P及CD79B基因突变分析
荧光定量PCR和一代基因测序技术检测结果显示，18例PCNSL组织MyD88L265P突变率为38.9％(7/18)；CD79B突变率为33.3％(6/18)，其中3例检测到CD79BY196突变(分别为CD79BY196F、CD79BY196C及CD79BY196S)，另外3例CD79B突变分别为CD79BF172V、CD79B E197G、CD79B N37H突变；MyD88L265P/CD79B共突变率为27.8%(5/18)，其中CD79B突变位点均不相同，分别为MyD88L265P/CD79BY196F、MyD88L265P/CD79BY196C、MyD88L265P/CD79BY196S、MyD88L265P/CD79BF172V、MyD88L265P/CD79B N37H。
2.3 PCNSL预后相关影响因素的单因素分析
病灶数量、病灶深部受累及肿瘤组织 CD79B 突变的PCNSL患者中位无进展生存期(median PFS，mPFS)差异均有统计学意义(P<0.05，表3)。Kaplan-Meier 生存曲线显示，与病灶单发患者比较，病灶多发患者mPFS更短(3个月vs. 未达到，P<0.05，HR=0.226，95%CI 0.046~1.107)，两者OS差异无统计学意义(P>0.05，图1)；与非深部受累患者比较，病灶深部受累患者mPFS 更短(3个月 vs. 未达到，P<0.05，HR=0.223，95%CI 0.054~0.919)，OS差异无统计学意义(P>0.05，图1)；与野生型患者比较，肿瘤组织中检测到MyD88L265P 突变型患者的mPFS和OS差异均无统计学意义(P>0.05)；与野生型患者比较，肿瘤组织中检测到CD79B突变型患者的mPFS更短(3个月vs. 未达到，P<0.05，HR=0.249，95%CI 0.065~0.952)，OS差异无统计学意义(P>0.05，图1)。
2.4 PCNSL 患者PFS影响因素的Cox回归分析结果
将单因素分析中差异有统计学意义的影响因素纳入Cox回归分析，结果显示，病灶深部受累(HR=0.135，95%CI 0.023~0.799，P<0.05)、肿瘤组织CD79B突变(HR=0.149，95%CI 0.028~0.800，P<0.05)是PCNSL患者疾病进展预后不良的独立危险因素(表4)。
2.5 MyD88L265P及CD79B基因突变对治疗反应的影响
7例MyD88L265P基因突变患者的客观缓解率(objective response rate，ORR)为42.9%(3/7)；6例CD79B基因突变患者ORR为33.3%(2/6)。伴发上述两种基因突变的患者中，治疗有效者与无效者的mPFS差异均有统计学意义(P=0.019、P=0.044)，而中位总生存期(mOS)比较差异均无统计学意义(P>0.05)(表5)。
3 讨论
收起
PCNSL是一种罕见的累及中枢神经系统的非霍奇金淋巴瘤，多继发于免疫功能缺陷患者，但近年来在免疫功能正常患者中的发病率也逐渐升高。PCNSL疾病进展迅速，早期诊断困难，疾病预后较差。PCNSL诊断的金标准仍为接受立体定向活检术或开颅手术，行病理学及免疫抗原检测确诊，但手术活检可能存在严重并发症的风险及活检无法触及的病变部位等手术禁忌。目前病损切除的预后意义尚存在争议。对于不能活检的患者，可行脑脊液检查，但其敏感度较低，尚无可替代活检的细胞因子或其他标志物。90%以上的PCNSL病理表现为DLBCL，其中以非GCB亚型多见[11]。本研究中18例PCNSL病理表现均为DLBCL，其中56%的患者为非GCB亚型。既往研究发现，非GCB亚型PCNSL预后较GCB亚型差[11]；本研究中非GCB亚型的mPFS与GCB亚型差异不明显，与既往研究结果不一致，可能与样本量较小有关。
国际结外淋巴瘤研究组织(International Extranodal Lymphoma Study Group，IELSG)提出的PCNSL预后评分系统，共纳入年龄、ECOG评分、乳酸脱氢酶(lactic dehydrogenase，LDH)水平、脑脊液蛋白水平、病灶累及脑深部(脑室旁、基底节、脑干、小脑)5个危险因素，目前已在临床广泛应用。本研究18例PCNSL初诊评估56%出现深部脑组织受累，脑组织深部受累者mPFS明显短于非深部受累者，且Cox回归分析结果显示脑组织深部受累是预后不良的独立危险因素，与IELSG评分系统一致。但本研究中PCNSL患者年龄、ECOG评分、LDH水平与预后的相关性不明显，可能与样本量小、随访时间短有关。本研究因部分患者颅内高压未行腰穿或拒绝腰穿，未收集到全部病例的脑脊液相关数据，未进一步行脑脊液分析。本研究中，初诊时PCNSL肿瘤多发者的mPFS明显短于单发者(3个月vs. 未达到)；患者性别及免疫组化BCL2、BCL6、MUM1是否阳性表达与预后的相关性不明显，可能与样本量较小、随访时间较短有关，有待扩大样本量及延长随访时间进一步观察。
PCNSL高度依赖于慢性活化的 BCR 信号转导，其特点是MyD88和CD79B基因频繁突变[12-13]。MyD88是一种重要的衔接蛋白，属于Toll样受体(Toll-like receptors，TLR)/白细胞介素(interleukin，IL)-1R家族，可介导多种细胞因子受体和TLR、JAK-STAT、核因子κB(nuclear factor kappa-B，NF-κB)等通路的信号转导，上述信号通路的失调诱导激活NF-κB复合物[14]，从而促进肿瘤免疫逃逸、肿瘤发生和进展，因此，抑制MyD88蛋白活化是一种潜在的治疗途径。PCNSL中影响MyD88基因TIR 结构域90%的突变是MyD88L265P[7]。MyD88L265P在其他血液肿瘤中少见[15]，是PCNSL较好的分子标志，多项研究认为脑脊液MyD88L265P检测是一种潜在的微创诊断方法[6,16-17]。本研究中PCNSL肿瘤组织中MyD88L265P突变率为38.9% (7/18)，与其他研究报道的突变率(33%~87%)一致[18-20]；在检测到MyD88L265P突变的7例中，除1例在2个疗程免疫化疗病灶进展死亡外，其余6例均接受至少6个疗程免疫化疗；7例的ORR为42.9%(3/7)；治疗有效患者的mPFS明显长于无效患者(32个月vs. 2个月)，但中位生存期差异无统计学意义(32个月vs. 17个月)。既往对于PCNSL中MyD88L265P突变的意义存在争议，本研究结果显示肿瘤组织 MyD88L265P 突变与患者PFS相关不明显，提示PCNSL 的生物学异质性。
已报道的PCNSL中CD79B突变率为6.7%~83.0%[10,21]，且大多数CD79B突变集中在Y196周围的免疫受体酪氨酸激活基序(ITAM)区域[22-23]。本研究在33.3%(6/18)PCNSL患者中检测到CD79B突变，其中3例为CD79BY196突变，其他3例分别为CD79B F172V、CD79B E197G、CD79B N37H突变，这在以往有关PCNSL的基因突变类型中少有报道，提示CD79B突变的复杂性。本研究结果显示，PCNSL肿瘤组织CD79B突变与患者 PFS 相关，且为预后不良的独立因素；在检测到CD79B突变6例的ORR为33.3%(2/6)，其中5例接受了至少6个疗程免疫化疗；治疗无效者的mPFS明显短于治疗有效者(2个月vs. 30个月)，但中位生存期差异无统计学意义(17个月vs. 30个月)。
本研究MyD88L265P/CD79B共突变5例PCNSL患者的ORR为20%(1/5)，其中4例接受了至少6个疗程免疫化疗；治疗有效者的mPFS、mOS与无效者比较差异均无统计学意义(40个月vs. 2个月，40个月vs. 17个月)。单因素分析显示，MyD88L265P/CD79B共突变与PFS相关不明显，但5例中，3例CD79BY196突变的患者均发生疾病进展，因此，MyD88L265P/CD79BY196共突变是否与PCNSL的不良预后相关，仍需进一步临床验证。虽然MyD88L265P、CD79B常被认为与NF-κB通路相关，但这两种分子均与其他通路有广泛交联，对PCNSL预后的影响及作用机制可能还与下游信号分子的效应总和相关。
本研究中所有PCNSL均以R-MTX 为基础方案进行治疗，初始治疗方案中不包含放疗。18例中，16例(88.9%)接受单纯免疫化疗，2例(例5、例13)因病灶进展辅以放疗，这2例肿瘤组织中均未检测到MyD88L265P、CD79B突变。促进PCNSL患者疾病进展、影响预后的因素较多，本研究的缺陷之一是仅对初诊时肿瘤组织中MyD88L265P、CD79B突变状态进行生存分析，因不同患者疾病状态、颅内压等条件的变化，未能检测初诊时脑脊液MyD88L265P、CD79B突变加以对照，也未能在病程中或疾病进展时再次取肿瘤组织或收集脑脊液动态监测基因突变，疾病进展是否与这两种基因的克隆演变相关尚需进一步观察。
总之，PCNSL是一种罕见的淋巴瘤，具有侵袭性高、预后差等特点，MyD88L265P、CD79B在肿瘤组织中的高突变率可为PCNSL的靶向治疗提供更有利的依据；肿瘤组织CD79B突变可能是PCNSL的不良预后因素。鉴于本研究样本量较小和随访时间较短，未来应进一步行多中心、大样本量研究以验证MyD88L265P及CD79B突变对 PCNSL的影响。
基金
收起
  • 国家自然科学基金(8226010026)
  • 兰州大学第二医院“萃英研究生指导教师”培育计划(201710)
文献
收起
参考文献 引证文献
排序方式：
[1]
Chukwueke U, Grommes C, Nayak L. Primary central nervous system lymphomas[J]. Hematol Oncol Clin North Am, 2022, 36(1): 147-159.
[2]
郭旭, 朴浩哲, 隋锐, 等. 微小RNA-106b在中枢神经系统肿瘤中调控作用研究进展[J]. 临床军医杂志, 2022, 50(8): 875-877, 880.
[3]
Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors[J]. J Neurooncol, 2006, 80(2): 159-165.
[4]
Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network[J]. Neuro-Oncology, 2016, 18(9): 1297-1303.
[5]
秦毅丹, 李佳, 裴晓晨, 等. 中枢神经系统淋巴瘤并发干燥综合征1例报告及文献复习[J]. 吉林大学学报(医学版), 2023, 49(1): 209-214.
[6]
Ferreri AJM, Calimeri T, Lopedote P, et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study[J]. Br J Haematol, 2021, 193(3): 497-505.
[7]
Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma[J]. Cancer Cell, 2017, 31(6): 833-843.e5.
[8]
Choi YS. Recent advances in the management of primary central nervous system lymphoma[J]. Blood Res, 2020, 55: 58-62.
[9]
Takashima Y, Sasaki Y, Hayano A, et al. Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma[J]. Oncotarget, 2018, 9(44): 27471-27486.
[10]
Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas[J]. Neuropathol Appl Neurobiol, 2016, 42(3): 279-290.
[11]
Niparuck P, Boonsakan P, Sutthippingkiat T, et al. Treatment outcome and prognostic factors in PCNSL[J]. Diagn Pathol, 2019, 14(1):56.
[12]
Zhang Y, Zhou DB. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment[J]. Chin Med J, 2020, 133(12): 1462-1469.
[13]
Zheng M, Perry A M, Bierman P, et al. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma[J]. Neuropathology, 2017, 37(6): 509-516.
[14]
Radke J, Ishaque N, Koll R, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma[J]. Nat Commun, 2022, 13(1): 2558.
[15]
Hattori K, Sakata-Yanagimoto M, Okoshi Y, et al. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma[J]. Br J Haematol, 2017, 177(3): 492-494.
[16]
Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma[J]. Blood, 2019, 133(5): 436-445.
[17]
陈锟,马晶晶, 王迪, 等. 脑脊液MyD88L265P基因突变对原发性中枢神经系统淋巴瘤预后的影响[J]. 中华检验医学杂志, 2022, 45(1): 51-57.
[18]
Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma[J]. Acta Neuropathol, 2016, 131(6): 865-875.
[19]
Hattori K, Sakata-Yanagimoto M, Suehara Y, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma[J]. Cancer Sci, 2018, 109(1): 225-230.
[20]
Zhou YY, Liu W, Xu ZJ, et al. Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes[J]. Neoplasia, 2018, 20(10): 1059-1069.
[21]
Zorofchian S, El-Achi H, Yan YQ, et al. Characterization of genomic alterations in primary central nervous system lymphomas[J]. J Neuro-Oncol, 2018, 140(3): 509-517.
[22]
O'neill SK, Getahun A, Gauld SB, et al. Monophosphorylation of CD79a and CD79b ITAM motifs initiates a SHIP-1 phosphatase-mediated inhibitory signaling cascade required for B cell anergy[J]. Immunity, 2011, 35(5): 746-756.
[23]
Yonese I, Takase H, Yoshimori M, et al. CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential[J]. Eur J Haematol, 2019, 102(2): 191-196.
2024年第49卷第1期
PDF下载
249
108
引用本文
BibTeX
文章信息
doi: 10.11855/j.issn.0577-7402.1223.2023.0528
  • 接收时间：2022-05-31
  • 首发时间：2025-11-23
  • 出版时间：2024-01-28
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期：2022-05-31
  • 录用日期：2022-10-14
基金
National Natural Science Foundation of China(8226010026)
国家自然科学基金(8226010026)
Project of "Cuiying Graduate Instructor" Training in the Second Hospital of Lanzhou University(201710)
兰州大学第二医院“萃英研究生指导教师”培育计划(201710)
作者信息
    兰州大学第二医院血液科，甘肃兰州 730030

通讯作者:

吴重阳，E-mail：
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/jfjyxzz/CN/10.11855/j.issn.0577-7402.1223.2023.0528
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
相关链接
论文
最新文章
热读文章
热点专题
内参
蓝皮书
产业发展报告
传播力报告
期刊分级目录
资讯
学术新闻
行业新闻
学术会议
行业会议
关于
关于我们
联系我们
北京市海淀区学院南路86号
100081
010-62199257
qkjq@cast.org.cn

中国科学技术协会版权所有 京ICP 备10216604号-4 海淀分局备案 1101084647
科技导报社主办 中国科协信息中心技术支持